scholarly journals Adverse events following mRNA vaccine administration from a busy orthopedic practice: A series of four cases

2022 ◽  
Author(s):  
Hussein A. Elkousy ◽  
Justin D. Khoriaty ◽  
Emily A. Vidal ◽  
Sara J. Vincent ◽  
Bridget A. Buras ◽  
...  
Keyword(s):  
Adverse Events ◽  
Vaccine Administration

Vocal Fold Immobility Following Vaccination

2020 ◽  
pp. 000348942096563
Author(s):  
Guy Talmor ◽  
Brandon Nguyen ◽  
Corina Din-Lovinescu ◽  
Boris Paskhover ◽  
Rachel Kaye
Keyword(s):  
Adverse Event ◽  
Adverse Events ◽  
Symptom Onset ◽  
Vocal Fold ◽  
Rare Complication ◽  
Adverse Event Reporting System ◽  
Vaccine Administration ◽  
Presenting Symptoms ◽  
Vocal Fold Immobility ◽  
The Relationship

Objective: Vocal fold immobility (VFI) may severely affect quality of life due to dysphonia and respiratory distress. Many etiologies of this disorder have been evaluated, however the relationship between VFI and vaccination has yet to be explored. The objective of this study was to identify the relationship between VFI and vaccine administration. Methods: The Vaccine Adverse Event Reporting System (VAERS) database was queried for patients exhibiting symptoms of VFI following vaccination. Patient demographics and clinical information including presenting symptoms, time of symptom onset, laterality, outcomes, and adverse events were documented. Results: Twenty-two patients were found to have VFI following vaccination. Of those reported, 13 patients were female (59.1%) and 8 were male (36.4%) with an average age of 48.4 years. Vaccinations for influenza, shingles, pneumococcus, and hepatitis B were reported. A majority of these cases were unilateral in nature (73.3%). Mean lag time from vaccination to symptom onset was 6.3 days (range 0-45 days). Five adverse events were reported, with 4 patients requiring intubation and tracheostomy. Conclusion: Vaccine administration may be associated with VFI and physicians should be cognizant of this potential adverse event. This is a rare complication with less reported cases than other post-vaccination cranial neuropathies. The difficulty in establishing an initial diagnosis and need for specialized evaluation by an otolaryngologist may result in under-reporting of such events. Further research is needed to delineate the exact pathophysiology of this complication and determine whether a causal relationship exists.

Adverse events diagnosed within three days of vaccine administration in dogs

2005 ◽  
Vol 227 (7) ◽  
pp. 1102-1108 ◽  
Author(s):  
George E. Moore ◽  
Lynn F. Guptill ◽  
Michael P. Ward ◽  
Nita W. Glickman ◽  
Karen K. Faunt ◽  
...  
Keyword(s):  
Adverse Events ◽  
Vaccine Administration

Adverse events after vaccine administration in cats: 2,560 cases (2002–2005)

2007 ◽  
Vol 231 (1) ◽  
pp. 94-100 ◽  
Author(s):  
George E. Moore ◽  
Andrea C. DeSantis-Kerr ◽  
Lynn F. Guptill ◽  
Nita W. Glickman ◽  
Hugh B. Lewis ◽  
...  
Keyword(s):  
Adverse Events ◽  
Vaccine Administration

scholarly journals Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC)

2019 ◽  
Vol 45 (1) ◽  
Author(s):  
L. Nicolosi ◽  
C. Rizzo ◽  
G. Castelli Gattinara ◽  
N. Mirante ◽  
E. Bellelli ◽  
...  
Keyword(s):  
High Risk ◽  
Adverse Events ◽  
Clinical Importance ◽  
European Medicines Agency ◽  
Vaccine Administration ◽  
Children's Hospital ◽  
Children’S Hospital ◽  
Control And Prevention ◽  
Low Incidence ◽  
High Risk Children

Abstract Background Invasive meningococcal disease is a serious global health threat in the world; in 2016, the European Centre for Disease Control and Prevention reported 3280 confirmed cases (including 304 deaths) of Invasive Meningococcal Diseases in Europe. In Italy, in 2017 were reported 200 cases 41% of which due to menB serogroup. From January 2013 the European Medicines Agency (EMA) has authorized the marketing of the meningococcal B vaccine 4CMenB. Methods The study aimed to evaluate and complement the safety profile of 4CMenB in high risk children accessing the vaccine service of the Bambino Gesù Children’s Hospital. All individuals aged six weeks or more receiving the meningococcal 4CMenB (Bexsero®) vaccine that approached the vaccine Centre at the Bambino Gesù Children’s Hospital in Rome, were asked to participate. All parents or caregivers of vaccinated individuals in the study period, were recruited and requested to answer to a questionnaire on adverse events following immunization (AEFI) observed after 7 days, starting from the date of vaccination. Results During the study period (October 2016–October 2017), we collected 157 completed questionnaires (out of 200 distributed). Of those 132 were first doses and 25 were booster administered doses. The median age of the study population was 4.5 years (range 0.29 to 26.8 years), the majority of subjects were high-risk individuals (64%) with chronic health conditions. Overall, 311 adverse events were reported in the 7 days after vaccine administration. In particular 147 events (47%) after administration of first dose and 58 (19%) after the booster doses. A large majority of those events, were of little clinical importance and concentrated in the 24 h after vaccine administration. No hospitalizations or Emergency Department access were reported. Conclusions Results of our study demonstrated that the Bexsero® vaccine is almost well tolerated, with a low incidence of severe AEFIs. Our results also shown that the occurrence of AEFIs is similar within healthy and high risk children.

scholarly journals Rotavirus Vaccination in the NICU: Where Are We? A Rapid Review of Recent Evidence

2020 ◽  
Vol 41 (S1) ◽  
pp. s380-s380
Author(s):  
lanie Sicard ◽  
Kristina Bryant ◽  
Martha Muller ◽  
Caroline Quach
Keyword(s):  
Adverse Events ◽  
The United States ◽  
Rapid Review ◽  
Rotavirus Vaccine ◽  
Live Attenuated Vaccine ◽  
Virus Shedding ◽  
Vaccine Administration ◽  
Rotavirus Vaccination ◽  
Rotavirus Vaccines ◽  
Relative Safety

Background: Rotavirus is a leading cause of viral acute gastroenteritis (AGE) in infants. Neonates hospitalized in neonatal intensive care units (NICUs) are at risk of rotavirus infections with severe outcomes. The administration of rotavirus vaccines is only recommended, in the United States and Canada, upon discharge from the NICU despite rotavirus vaccine being proven safe and effective in these populations, due to risks of live-attenuated vaccine administration in immunocompromised patients and theoretical risks of rotavirus vaccines strains shedding and transmission. We summarized recent evidence regarding rotavirus vaccines administration in the NICU setting and safety of rotavirus vaccines in preterm infants. Methods: We conducted a rapid review of the literature from the past 10 years, searching Medline and Embase, including all study types except reviews, reporting on rotavirus vaccine 1 and rotavirus vaccine 5; NICU setting; shedding or transmission; and/or safety in preterm. One reviewer performed data extraction and quality assessment. Results: In total, 31 articles were analyzed. Vaccine-derived virus shedding following rotavirus vaccination existed for nearly all infants, mostly during the first week after dose 1, with rare transmission described only in the household setting. No case of transmission in the NICU was reported. Adverse events were mild to moderate, occurring in 10%–60% of vaccinated infants. Extreme premature infants or with underlying gastrointestinal failure requiring surgery presented more severe adverse events. Conclusions: Recommendations regarding rotavirus vaccine administration in the NICU should be reassessed in light of the relative safety and absence of transmission of rotavirus vaccine strains in the NICU.Funding: NoneDisclosures: Sicard Mélanie: I reference the use of rotavirus vaccines in the NICU setting, which is not recommended; I discuss possible reassessment of these recommendations.

Incidence of and risk factors for adverse events associated with distemper and rabies vaccine administration in ferrets

2005 ◽  
Vol 226 (6) ◽  
pp. 909-912 ◽  
Author(s):  
George E. Moore ◽  
Nita W. Glickman ◽  
Michael P. Ward ◽  
Kathy S. Engler ◽  
Hugh B. Lewis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Rabies Vaccine ◽  
Vaccine Administration

scholarly journals SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

2021 ◽  
Vol 55 ◽  
pp. 70
Author(s):  
Rine Christopher Reuben ◽  
Lillian Yami Adogo
Keyword(s):  
Public Health ◽  
Adverse Events ◽  
Vaccine Hesitancy ◽  
Free World ◽  
Vaccine Administration ◽  
Public Health Challenges ◽  
Severe Adverse Events ◽  
Underlying Pathophysiology

The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.

Postvaccination Adverse Events

2010 ◽  
Vol 44 (12) ◽  
pp. 16
Author(s):  
STEPHEN I. PELTON
Keyword(s):  
Adverse Events
Sign in / Sign up

Export Citation Format

Share Document